ANBITION s.r.l., is an innovative start-up company registered at the business register of Naples, Italy
REA number: NA-992795.
In 1971, Judah Folkman published the first hypothesis that tumor growth is angiogenesis dependent, thus paving the way to the development of anti-angiogenic therapy.
The anti-angiogenic therapy is essentially based on the use of biological drugs or biotherapeutics (monoclonal antibodies and recombinant proteins).
